2.76
-0.11 (-3.83%)
| Previous Close | 2.87 |
| Open | 2.87 |
| Volume | 25,701 |
| Avg. Volume (3M) | 49,983 |
| Market Cap | 88,547,600 |
| Price / Book | 1.78 |
| 52 Weeks Range | |
| Earnings Date | 30 Mar 2026 |
| Diluted EPS (TTM) | -19.29 |
| Total Debt/Equity (MRQ) | 0.23% |
| Current Ratio (MRQ) | 7.43 |
| Operating Cash Flow (TTM) | -12.54 M |
| Levered Free Cash Flow (TTM) | -8.01 M |
| Return on Assets (TTM) | -19.14% |
| Return on Equity (TTM) | -51.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Dogwood Therapeutics, Inc. | Mixed | - |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.07% |
| % Held by Institutions | 7.95% |
| 52 Weeks Range | ||
| Median | 12.00 (334.78%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Feb 2026 | 12.00 (334.78%) | Buy | 2.93 |
| 30 Jan 2026 | 12.00 (334.78%) | Buy | 2.79 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 |
| 12 Jan 2026 | Announcement | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |